Abstract
Studies on genetic robustness recently revealed transcriptional adaptation (TA) as a mechanism by which an organism can compensate for genetic mutations through activation of homologous genes. Here, we discovered that genetic mutations, introducing a premature termination codon (PTC) in the amyloid precursor protein-b (appb) gene, activated TA of two other app family members, appa and amyloid precursor-like protein-2 (aplp2), in zebrafish. The observed transcriptional response of appa and aplp2 required degradation of mutant mRNA and did not depend on Appb protein level. Furthermore, TA between amyloid precursor protein (APP) family members was observed in human neuronal progenitor cells; however, compensation was only present during early neuronal differentiation and could not be detected in a more differentiated neuronal stage or adult zebrafish brain. Using knockdown and chemical inhibition, we showed that nonsense-mediated mRNA decay (NMD) is involved in degradation of mutant mRNA and that Upf1 and Upf2, key proteins in the NMD pathway, regulate the endogenous transcript levels of appa, appb, aplp1, and aplp2 In conclusion, our results suggest that the expression level of App family members is regulated by the NMD pathway and that mutations destabilizing app/APP mRNA can induce genetic compensation by other family members through TA in both zebrafish and human neuronal progenitors.
Keywords
NMD
Upf1
amyloid precursor protein
mutant
transcriptional adaptation
zebrafish
MeSH 主题词
Zebrafish
Animals
Amyloid beta-Protein Precursor/genetics,metabolism
Nonsense Mediated mRNA Decay
Humans
Zebrafish Proteins/metabolism,genetics
RNA, Messenger/metabolism
Neural Stem Cells/metabolism
Mutation
Animals, Genetically Modified
化学物质
Amyloid beta-Protein Precursor
Zebrafish Proteins
RNA, Messenger
作者与单位
共 7 位作者,点击展开单位 / ORCID
Rahmati Maryam
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden.
Chebli Jasmine
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden.
Kumar Banote Rakesh
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden.
Roselli Sandra
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden.
Agholme Lotta
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden.
Zetterberg Henrik
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden. | Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N #BG, United Kingdom. | Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 41, Sweden. | United Kingdom Dementia Research Institute, London W1T 7NF, United Kingdom. | Hong Kong Center for Neurodegenerative Diseases, 17 Science Park W Ave, Hong Kong, China. | Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin 53792.
Abramsson Alexandra
ORCID
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 45, Sweden alexandra.abramsson@gu.se.